NKGen Biotech Announces Publication in Journal of Cancer


SANTA ANA, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — NKGen Biotech, a biotechnology firm harnessing the facility of the physique’s immune system by the event of pure killer cell therapies, right this moment introduced a publication in the peer-reviewed Journal of Cancer Research and Cellular Therapeutics entitled “Durable responses using SNK01 autologous enhanced natural killer cells and pembrolizumab for chemotherapy-resistant advanced sarcoma: Case reports, review of literature, and future perspectives.”

The paper by Gordon et al. discloses enduring response information in chemotherapy resistant metastatic sarcoma sufferers who had been handled with SNK01, autologous enhanced pure killer cell remedy, and pembrolizumab, an immune checkpoint inhibitor, together with a overview of literature and future views on the use of SNK01 in superior sarcoma.

“We are pleased to be able to share the promising results of our SNK01 natural killer cell therapy in combination with pembrolizumab, in these two important case studies since metastatic sarcoma is typically associated with poor outcomes when treated with standard regimens,” commented Paul Song, M.D., Vice Chairman of NKGen Biotech. “It is encouraging to see that Patient #1, despite being PD-L1 negative and having failed prior pembrolizumab, eventually showed a gradual tumor reduction with a 47% partial response, after which the patient underwent two surgical resections and achieved a sustained remission. Of note is that the patient has safely been on this regimen for almost 35 months without any toxicity at all and remains no evidence of disease.”

“Patient #2 has low PD-L1 expression and had failed prior nivolumab. The patient showed a gradual reduction in tumor size, achieving a 38% partial response,” added Dr. Song, “This response data is very promising especially since both patients had failed prior immune checkpoint inhibitor therapy. It appears that SNK01 might be able to change the tumor microenvironment and suggests that SNK01 plus pembrolizumab has the potential to be a viable therapeutic option for patients with metastatic sarcoma, and especially in PD-L1 negative and low expressing tumors. Further studies are warranted, and we look forward to confirming these findings in a Phase II clinical trial.”

See also  The Law Offices of Timothy L. Miles Reminds Investors of a Lawsuit Against Fulgent Genetics, Inc.

The encouraging information from these two case studies suggests SNK01 mixed with pembrolizumab could also be a viable salvage remedy routine for chemotherapy-resistant superior sarcoma with manageable toxicity. The information additionally helps current proof that pure killer cells mediate a positive response to immune checkpoint inhibitor remedy whereas lowering immune-related adversarial occasions.

About NKGen Biotech

NKGen Biotech, Inc. is a clinical-stage biotechnology firm centered on the event and commercialization of revolutionary autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging our proprietary cell growth and activation expertise and cutting-edge cell manufacturing experience, now we have the flexibility to infinitely develop pure killer cells whereas considerably enhancing cytotoxicity throughout our peripheral blood-derived merchandise. NKGen Biotech’s lead product candidate, SNK01, is at the moment in scientific trials for the therapy of superior refractory strong tumors each as a monotherapy and in mixture with different brokers, together with checkpoint inhibitors and cell engagers. NKGen Biotech is dedicated to the imaginative and prescient of executing on our scientific methods with the aim of commercializing our NK cell therapies to assist save and maintain sufferers’ lives worldwide. The firm and its commercially licensed cGMP facility are headquartered in Santa Ana, California, USA. For extra data, please go to www.nkgenbiotech.com.

Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications

Source link


Please enter your comment!
Please enter your name here